MORRISVLLE – A startup developing a device for the treatment of osteoarthritis with technology from Duke University has raised a new round of funding. Sparta Biomedical says the round was “heavily oversubscribed” but did not disclose the amount.

Sparta did raise $5 million in 2021.

Have aching knees? Duke researchers spearhead development of gel-based cartilage solution

“The secured capital will accelerate Sparta’s preparations for the Investigational Device Exemption study preparations of its breakthrough device, Ormi.,” Sparta said in the announcement. However, the device has yet to secure FDA approval.

“This capital infusion is a strong testament to Sparta’s trajectory since our last financing in 2021,” said Dimitrios Angelis, co-founder and president of Sparta Biomedical, in a statement.  “This accomplishment underscores the hard work and expertise of clinical and regulatory advisors, and manufacturing and lab partners. We consider ourselves fortunate to have them as partners and look forward to continuing this journey together.”